NASDAQ: SRZNSurrozen Inc Stock
$9.60-0.15 (-1.54%)
Updated Apr 21, 2025
SRZN Price
$9.60
Fair Value Price
$12.97
Market Cap
$31.50M
52 Week Low
$6.00
52 Week High
$18.17
P/E
-0.44x
P/B
-1.47x
P/S
3.95x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.66M
Earnings
-$63.56M
Gross Margin
100%
Operating Margin
-596.56%
Profit Margin
-596.6%
Debt to Equity
-3.27
Operating Cash Flow
-$18M
Beta
0.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SRZN Overview
Surrozen Incorporated is a biotechnology company that is developing tissue-specific antibodies to treat diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company's products in pipeline include SZN-043, a tissue-specific R-spondin mimetic for the treatment of severe liver disease, and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen was founded in 2015 and is headquartered in South San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SRZN's potential to beat the market
- SRZN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SRZN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important SRZN news, forecast changes, insider trades & much more!
SRZN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SRZN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SRZN ($9.60) is undervalued by 26% relative to our estimate of its Fair Value price of $12.97 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SRZN ($9.60) is significantly undervalued by 26% relative to our estimate of its Fair Value price of $12.97 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SRZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SRZN due diligence checks available for Premium users.
Valuation
SRZN fair value
Fair Value of SRZN stock based on Discounted Cash Flow (DCF)
Price
$9.60
Fair Value
$12.97
Undervalued by
26.00%
SRZN ($9.60) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SRZN ($9.60) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SRZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SRZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.44x
Industry
-184.27x
Market
27.14x
SRZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.47x
Industry
4.04x
SRZN's financial health
Profit margin
Revenue
$655.0k
Net Income
-$28.0M
Profit Margin
-4,280.8%
SRZN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SRZN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$48.5M
Liabilities
$69.8M
Debt to equity
-3.27
SRZN's short-term assets ($38.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SRZN's long-term liabilities ($62.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SRZN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SRZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.5M
Investing
-$19.0k
Financing
$91.0k
SRZN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SRZN vs Biotech Stocks
Surrozen Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.